Critical Comparison: BioLargo (BLGO) vs. Its Rivals

BioLargo (NASDAQ:BLGO) is one of 33 publicly-traded companies in the “Chemicals & allied products” industry, but how does it weigh in compared to its competitors? We will compare BioLargo to related businesses based on the strength of its earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Valuation & Earnings

This table compares BioLargo and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BioLargo	$12.23 million	-$3.50 million	-8.00
BioLargo Competitors	$6.85 billion	$211.64 million	66.85

BioLargo’s competitors have higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

BioLargo has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500. Comparatively, BioLargo’s competitors have a beta of 1.81, indicating that their average stock price is 81% more volatile than the S&P 500.

Profitability

This table compares BioLargo and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioLargo	-16.53%	-58.35%	-32.12%
BioLargo Competitors	-591.84%	5.15%	-0.65%

Analyst Recommendations

This is a summary of current recommendations and price targets for BioLargo and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLargo	0	0	0	0	N/A
BioLargo Competitors	139	1250	1568	44	2.51

As a group, “Chemicals & allied products” companies have a potential upside of 15.66%. Given BioLargo’s competitors higher possible upside, analysts clearly believe BioLargo has less favorable growth aspects than its competitors.

Institutional & Insider Ownership

0.0% of BioLargo shares are owned by institutional investors. Comparatively, 68.3% of shares of all “Chemicals & allied products” companies are owned by institutional investors. 20.3% of BioLargo shares are owned by company insiders. Comparatively, 10.3% of shares of all “Chemicals & allied products” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

BioLargo competitors beat BioLargo on 8 of the 10 factors compared.

BioLargo Company Profile

BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.